Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial
- E. Matino
- •
- E. Tavella
- •
- M. Rizzi
- •
- G. Avanzi
- •
- D. Azzolina
- •
- Antonio Battaglia
- •
- Paolo Becco
- •
- M. Bellan
- •
- G. Bertinieri
- •
- M. Bertoletti
- •
- G. F. Casciaro
- •
- L. Castello
- •
- Umberto Colageo
- •
- D. Colangelo
- •
- Davide Comolli
- •
- Martina Costanzo
- •
- Alessandro Croce
- •
- Davide D’Onghia
- •
- F. Della Corte
- •
- Luigi De Mitri
- •
- Valentina Dodaro
- •
- Filippo Givone
- •
- A. Gravina
- •
- L. Grillenzoni
- •
- G. Gusmaroli
- •
- R. Landi
- •
- A. Lingua
- •
- R. Manzoni
- •
- V. Marínoni
- •
- Bianca Masturzo
- •
- R. Minisini
- •
- Marina Morello
- •
- A. Nelva
- •
- Elena Ortone
- •
- Rita Paolella
- •
- G. Patti
- •
- A. Pedrinelli
- •
- M. Pirisi
- •
- Lidia Ravizzi
- •
- E. Rizzi
- •
- D. Sola
- •
- Mariolina Sola
- •
- Nadir Tonello
- •
- S. Tonello
- •
- Gigliola Topazzo
- •
- Aldo Tua
- •
- P. Valenti
- •
- R. Vaschetto
- •
- V. Vassia
- •
- E. Zecca
- •
- Nicoletta Zublena
- •
- P. Manzoni
- •
- P. Sainaghi
Enhanced Details
Abstract
As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized do...
As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double-blind placebo-controlled trial. A total of 218 hospitalized adult patients with moderate-to-severe COVID-19 were randomized to receive 800 mg/die oral bovine lactoferrin (n = 113) or placebo (n = 105), both given in combination with standard COVID-19 therapy. No differences in lactoferrin vs. placebo were observed in the primary outcomes: the proportion of death or intensive care unit admission (risk ratio of 1.06 (95% CI 0.63–1.79)) or proportion of discharge or National Early Warning Score 2 (NEWS2) ≤ 2 within 14 days from enrollment (RR of 0.85 (95% CI 0.70–1.04)). Lactoferrin showed an excellent safety and tolerability profile. Even though bovine lactoferrin is safe and tolerable, our results do not support its use in hospitalized patients with moderate-to-severe COVID-19.